CCL5 and neoplasm: Significant reduction of tumor volume was observed in all the treatment groups, with tumor inhibition rates of 51.19, 53.28 and 34%, respectively, for Group I (SG511-CCL5-ODD), Group II (NK-92), Group III (SG511-CCL5-ODD92), when compared with the control group (P<0.05) on day 14 after treatment, and 46.15, 46.42 and 32.7% on day 21, 61.04, 46.81 and 31.46% on day 28, respectively (Fig. 5A).